Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial

This RCT in China (n=443) found low-dose capecitabine maintenance therapy (650 mg/m2 twice a day) for 1 year after a course of standard adjuvant chemotherapy was linked to improved 5-year disease-free survival (82.8% v 73.0%; HR 0.64; 95% CI 0.42-0.95]; P=0.03) v observation.

Journal of the American Medical Association